Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Return on Sales (2017 - 2025)

VYNE Therapeutics' Return on Sales history spans 9 years, with the latest figure at 0.06% for Q4 2025.

  • For Q4 2025, Return on Sales rose 3.0% year-over-year to 0.06%; the TTM value through Dec 2025 reached 0.06%, down 1.0%, while the annual FY2025 figure was 0.44%, 50.0% up from the prior year.
  • Return on Sales reached 0.06% in Q4 2025 per VYNE's latest filing, up from 0.08% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 75.08% in Q1 2022 to a low of 75.31% in Q4 2022.
  • Average Return on Sales over 5 years is 7.77%, with a median of 0.2% recorded in 2023.
  • Peak YoY movement for Return on Sales: soared 11714bps in 2022, then crashed -7518bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 11.71% in 2021, then crashed by -543bps to 75.31% in 2022, then soared by 99bps to 0.47% in 2023, then surged by 80bps to 0.1% in 2024, then surged by 35bps to 0.06% in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Return on Sales are 0.06% (Q4 2025), 0.08% (Q2 2025), and 0.04% (Q1 2025).